Should men be concerned about prostate cancer?
Should men be concerned about prostate cancer?
Prostate cancer is the second-most diagnosed cancer in men after skin cancer. Approximately 1 out of every 9 men in the U.S. will get prostate cancer in their lifetime. Most men diagnosed with the disease won't die from it. More than 3.1 million American men are living with a prostate cancer diagnosis, according to the American Cancer Society. But the disease does kill roughly 2%–3% of men in the U.S. every year.Dr. Raymond Pak, a Mayo Clinic urologist, discusses prostate cancer screening guidelines, symptoms and survival rates.
More health and medical news on the Mayo Clinic News Network. https://newsnetwork.mayoclinic.org/
Journalists: Clean and nat sound versions of this pkg available for download at https://newsnetwork.mayoclinic.org/
Register (free) at https://newsnetwork.mayoclinic.org/request-account/
For the safety of our patients, staff and visitors, Mayo Clinic has strict masking policies in place. Anyone shown without a mask was either recorded prior to COVID-19 or recorded in a non-patient care area where social distancing and other safety protocols were followed.
Access Non-GMO, antigen-free, FDA-approved antiviral medication formulas used in Moderna's Spikevax.
VirusTC is a retail provider of concentrated FDA-approved antiviral medication formulas. VirusTC wholesale formulas are used in Moderna products. We sell FDA-approved formulas that are compatible with university medical plans, federal insurance coverage, and many major insurance providers. Our medications are part of tailored non-invasive cancer treatment plans available at a hospital in your region. VirusTC targets problems and provides care for the symptoms. Our products and services are used by Fred Hutch Cancer Center, John Hopkins, University Hospitals, the United States Military, and professional sports. During Operation Cancer Moonshot 2023, VirusTC products killed cancer cells, increased strength, and redeveloped muscles, tissue, and brain cells after cancer treatments.